Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01760291 · ClinicalTrials.gov registry record · NA

Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology

A NA study, sponsored by Boston Scientific Corporation.

Completed
Registry status
NA
Development phase
576
Enrollment target

NCT01760291 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 576 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01760291, a NA study, has completed, sponsored by Boston Scientific Corporation.

COMPLETED
Registry status
NA
Development phase
576 participants
Enrollment target

Study Summary

To provide additional information about the safety and efficacy of the WATCHMAN LAA Closure Technology

Interventions

  • DEVICE WATCHMAN LAA Closure Technology

Trial Details

FieldValue
Enrollment Target 576 participants
Start Date 2012-09
Est. Completion 2019-04
Phase NA

Sponsor

Boston Scientific Corporation

280 total trials

What the Registry Record Tells You About NCT01760291

The ClinicalTrials.gov registry entry for NCT01760291 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 576 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which WATCHMAN LAA Closure Technology is the first listed.

NCT01760291 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01760291 about?

NCT01760291 is a clinical study titled "Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology". To provide additional information about the safety and efficacy of the WATCHMAN LAA Closure Technology

What is the current status of trial NCT01760291?

This trial is currently completed. It is a NA study. The enrollment target is 576 participants. The study started on 2012-09. Estimated completion is 2019-04.

What interventions are being tested in trial NCT01760291?

The interventions under investigation include: WATCHMAN LAA Closure Technology (DEVICE).

Who is sponsoring clinical trial NCT01760291?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.